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Tuberculosis (TB) epidemic is a global health challenge, and WHO estimated the incidence of the new cases 
reaching 11.1 million people in 2017. Indonesia is classified as a high TB burden country, with 8% of its 
population infected by TB and ranks third in the world. Type-2 diabetes mellitus (T2DM) is known 
comorbidity for TB patients. TB-T2DM patients have a higher chance of morbidity, mortality, relapse, 
bacterial resistance, treatment failure, and slower sputum conversion than TB patients without T2DM. 
Recent studies suggest that metformin may have a potential synergistic role for TB-T2DM patients. 
Metformin has immunomodulator properties that can improve the body's immune response and 
inflammatory response against TB in individuals with T2-DM.  
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Tuberculosis (TB) is an infectious disease 
that has become a global health issue with the 
estimated incidence of new cases by the World 
Health Organization (WHO), reaching 11.1 
million people in 2017. An increase in the 
estimated incidence of new TB cases by 600 
thousand people compared to 2016. Indonesia 
is one of the countries with a high TB burden 
and ranks third with 8% after India and China. 
Cases of pulmonary tuberculosis have an 
average cure rate of 83% in the world; however, 
the emergence of comorbidities such as HIV 
infection or diabetes mellitus (DM) is 
susceptible to increasing the risk of TB infection 
accompanied by the appearance of 
complications in treatment [1–3]. Some 
literature shows that 5.4-44% of pulmonary TB 
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patients also have DM [4]; Indonesia has 10.3 
million population aged 20-79 years with DM. 
The mechanism of the increased risk of TB 
in DM patients is unclear, but some literature 
states that there is an association of T cell 
responses and abnormal cytokines that can 
increase the inflammatory process in the body 
[5–7] . Also, it mentioned a decrease in the 
function of the innate and adaptive immune 
response that causes latent TB patients with DM 
to be more active than people without DM [8,9]. 
Some other studies also mention a relationship 
between TB and DM patients and undesirable 
treatment outcomes such as slower sputum 
conversion, higher mortality rates, and a higher 
risk of TB relapse after being declared healed as 
much as three times [10]. 
Metformin (MET) is the first-line oral 
antidiabetic drug recommended for patients 
with type 2 DM [11]. This drug can reduce blood 
sugar levels in the body by reducing liver 
glucose production, slowing glucose absorption 
in the small intestine, and increasing insulin 
sensitivity for glucose utilization [12]. Several 
recent studies have concluded that MET is a 
potential role as an adjunct therapy to increase 
the effectiveness of TB treatment [11]. Another 
study found that the use of MET to be combined 
with a TB regimen increased the rate of 
treatment success and decreased the rate of 
relapse in TB patients with DM [12,13]. 
In an in vivo study, MET can increase the 
effects of autophagy on macrophages through 
phagolysosome fusion activated from AMP-
activated by protein kinase (AMPK), triggers the 
production of reactive oxygen species from 
mitochondria (mROS), and inhibit the growth of 
Mycobacterium tuberculosis (Mtb) (AMB) [14–
16]. The follow-up in vitro study found fewer 
Mycobacterium germs and lower mortality in 
mice given a combination of isoniazid (INH) and 
MET compared to mice that only got INH [14]. 
Besides, one cohort study also mentioned that 
MET administration might be useful in TB-DM 
patients with a complicated pulmonary cavity 
[17]. 
Considering the TB case with comorbid DM 
is a unique population with a high vulnerability 
level, we present a literature review entitled 
The Role of Metformin in Tuberculosis Therapy, 
which is expected to help Indonesia achieve the 
WHO's post-2015 End TB goal. 
 
2. Experimental section  
This is a review of metformin role in 
tuberculosis patients with type-2 diabetes 
mellitus. We utilized four databases for the 
literature searching process that consists of 
PubMed, Science Direct, Cochrane Library, and 
GoogleScholar between November 2019 and 
June 2020. 
 
3. Results and Discussion 
3.1. Tuberculosis and Diabetes Mellitus 
Epidemiology  
Tuberculosis (TB) still ranks the first cause 
of death caused by a single microorganism in the 
world, even if there has been a lower death rate 
by active TB infection since 1990. World Health 
Organization (WHO) estimation in 2017 found 
that TB incidence only reached 11.1 million, 
which means an increase of 600 thousand 
population compared to 2016. Indonesia is a 
country with a high TB burden, with 8% of the 
population infected with TB and ranks third 
after India and China in the world. A strategy to 
eradicate the global TB epidemic was launched 
by WHO, End TB Strategy, in 2016 with the 
primary goal of reducing 90% of TB deaths and 
80% of TB incidence in 2030 when compared to 
2015 [3]. 
In recent decades, the epidemic of diabetes 
mellitus (DM) is one of the global health 
challenges with a prevalence rate that far 
exceeds the predictions [5]. Some causes that 
might increase non-communicable diseases 
include the aging population, urbanization, and 
unhealthy living style. The latest census from 
the International Diabetes Federation (IDF) in 
2015 projected that there were 415 million 
people in the world with DM who would 
increase to 642 million by 2040. The study also 
mentions that 85-95% of all the world 
population with DM has type 2 diabetes [2]. 
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An increase in the incidence of DM is 
considered only experienced by residents in 
developed countries with high incomes, but it is 
estimated that 80% of the world's population 
who suffer from DM live in low and middle-
income countries with the highest rate of 
increase also occurs in residents in these 
countries. This increase has a significant impact 
on the economic sector and public health 
because countries with low-middle income have 
a high prevalence of infectious diseases and the 
low availability of health facilities. The 
confluence between infectious and non-
communicable diseases increases the mortality 
and morbidity rates associated with comorbid 
diseases, increases steps to control the spread of 
infectious diseases, and re-emergence of 
intracellular bacterial infections [5]. 
3.2. Diabetes Mellitus-Tuberculosis 
Comorbidity  
Individuals with DM have a higher risk of 
developing infectious diseases, and their 
complications with a higher death rate are twice 
as high as individuals without DM [5]. Reducing 
the impact of this double burden is still tricky 
because the mechanism underlying the 
increased risk of infection in DM patients 
remains unclear. However, various studies and 
research have been conducted, suggesting 
different cytokine responses when fighting 
infectious diseases [5,6]. Some literature states 
that there are 5.4-44% of individuals with 
pulmonary TB who also have DM [4,13]. 
The relationship between type 2 DM and 
TB and the effect of a combination of both as a 
disease in pathophysiology has been known for 
a long time, but there are still no studies that can 
scientifically prove the relationship between the 
two [6]. Clinicians and researchers are still 
unable to determine whether DM causes TB or 
TB to cause clinical manifestations of DM [8]. 
Eighty years ago, DM patients who did not die 
from a diabetic coma were more likely to die of 
TB and its complications. This phenomenon 
began to diminish with the discovery of insulin 
therapy for DM and antibiotics for TB. However, 
in the 1980s, the reappearance of these two 
diseases as comorbidities due to the DM 
pandemic [7] was influenced by increased 
obesity rates, changes in diet, decreased 
physical activity, and an aging population [9]. 
Some literature shows that 5.4-44% of 
pulmonary TB patients also have DM [4]; 
Indonesia has 10.3 million population aged 20-
79 years with DM. 
One meta-analysis of 13 observational 
studies states that patients with DM have a 3.1 
times greater risk of infection with pulmonary 
TB when compared to individuals without DM. 
At the same time, more than 40 other studies, 
including four cohort studies, 16 retrospective 
studies, and 17 case-control studies, also found 
that patients with DM were more likely to be 
infected with TB when compared to individuals 
without DM [6,7]. Besides, patients with TB and 
DM also have a higher risk of morbidity, 
mortality, relapse, slower sputum conversion, 
resistance, and treatment failure when 
compared to TB patients without DM [9,10]. 
3.3. Immunity Response in Individuals with 
Tuberculosis and Diabetes Mellitus  
Several studies have shown convincing 
evidence about the causal relationship between 
DM and decreased an individual's immunity to 
TB [8]. Studies in experimental animals have 
shown that diabetic rats intentionally given M. 
tuberculosis (Mtb) had more bacterial counts 
than mice with normal blood sugar levels [7,8]. 
Mice with chronic diabetes have significantly 
lower levels of interferon-gamma (IFN-gamma), 
interleukin-12 (IL-12), and T helper 1 (Th1) 
production in early adaptive immunity against 
M. tuberculosis bacterial infection [8,9]. Other 
literature also causes a state of hyperglycemia, 
and poor blood sugar control in individuals with 
DM will create maladaptive microvascular 
structures and decreased lung tissue perfusion, 
which results in optimized immune surveillance 
[7,8]. 
Research using human plasma cells shows 
that high insulin levels can depict a decrease in 
Th1 immunity due to an imbalance between Th1 
cells and Th2 cells, IFN-gamma, and IL-4 [8]. 
Immunity to Mtb requires a response from Th1 
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and Th17 cells with IL-2. IFN-gamma, TNF-
alpha, IL-17, and IL-23 also play an essential role 
in the induction and sustainability of a 
protective immune response to TB infection 
[6,7]. Also, one literature comparing ex vivo Th1 
cytokine production shows that the nonspecific 
IFN-gamma levels of individuals with DM are far 
below those without DM [7,8]. Numerous 
studies have noted an inverse relationship 
between IFN-gamma levels and the HbA1c 
results of the entire population [8,9]. 
Individuals with DM also experience a decrease 
in neutrophil function due to chemotaxis and 
higher oxidation reactions when compared to 
the control group [8]. The bactericidal function 
of leukocytes also decreases in individuals with 
poor glucose control [6,8]. 
An in vitro study was conducted to look at 
the initial performance of innate immunity 
against TB by infecting human blood monocytes 
with and without DM, which shows that there is 
a decrease in the ability of individual monocytes 
with DM to bind and phagocytosis of the Mtb 
bacteria due to alterations in the C3 
complement that serves to phagocytosis Mtb 
[6,7,15]. This reduction in efficiency in 
performing phagocytosis is believed to 
contribute to an increased risk of infection and 
prolong treatment duration. The results of this 
study are similar to the literature conducting in 
vivo studies in mice [2,8]. 
Several immunological studies conducted 
in the last few years mentioned that individuals 
with DM infected with TB would trigger an 
excess paradoxical inflammation response 
(paradoxical hyper-inflammatory response), 
which can be seen from the increase in IFN-
gamma production, IL-2, TNF-alpha, and factors 
forming granulocyte-macrophage colonies 
[5,6,14,15]. This inflammation response will 
result in an increase in various cytokines by 
decreasing T-regulation (Treg) cells, which will 
result in a physiological decrease of innate 
immunity to Mtb [5,6,15]. 
The increased risk of relapse, treatment 
failure, and mortality during TB treatment in 
patients with DM is in line with various data 
from in vivo and in vitro studies, which 
concluded that DM could interfere with cell 
immunity [6,9,10]. Other in vitro studies found 
that poor blood sugar control, judged by HbA1c, 
also affects the innate immune response and 
type 1 cytokine [9,10,15]. 
3.4. Pharmacological Management 
Problems of Patient with Tuberculosis 
and Mellitus Diabetes  
The combination of rifampicin, isoniazid, 
ethambutol, and pyrazinamide is the current 
gold standard treatment of anti-TB therapy [10–
12]. The long duration of treatment, which is 6-
12 months, and non-compliance of individuals 
in the consumption of this therapy led to the 
evolution of various Mtb strains that were 
resistant to treatment [11]. There are 5% of all 
TB cases in the world that are estimated to be 
Mtb that is resistant to at least one first-line 
anti-TB drug that makes pharmacological 
interventions less effective so that alternative 
treatments are needed outside these first-line 
standard standards. Based on various studies 
that have been carried out, bacteria can become 
resistant to antibiotics in two ways: genetic 
mutation and bacterial persistence ability when 
given antibiotics [5,11]. 
Several studies have found that TB 
infection can worsen glucose tolerance in 
individuals with or without DM (12). Patients 
with DM have a higher susceptibility because 
the use of rifampicin in TB treatment can 
directly cause hyperglycemia and have 
interactions with oral antidiabetic drugs [8–10]. 
A study in Indonesia showed that TB patients 
with DM had serum rifampicin concentrations 
that were 53% lower than TB patients without 
DM, where low serum TB drug concentrations 
had an association with failure of TB treatment 
and Mtb resistance [8]. Besides, the side effects 
of peripheral neuropathy from isoniazid 
treatment can worsen in DM patients; therefore, 
pyridoxine is usually given to TB patients with 
DM [9,10]. 
A retrospective population-based cohort 
study conducted in 2017 compared the 
incidence of TB in patients newly diagnosed 
with type 2 diabetes who were given metformin 
or sulfonylureas for at least two years from the 
Metformin Role in Diabetic Patients with Tuberculosis: a Review  
 
 
J. Trop. Pharm. Chem. 2021. Vol 5. No. 3.   
p-ISSN: 2087-7099; e-ISSN: 2407-6090 
268 
diagnosis of DM. Multivariate analysis 
conducted in both groups found that the group 
given metformin had a lower risk of contracting 
TB than the group given sulfonylureas [18]. This 
study also shows that metformin can reduce the 
risk of progression of active TB in patients with 
type 2 DM [18,19]. 
3.5. The Role of Metformin in Tuberculosis 
Therapy  
Metformin hydrochloride (MET) is a first-
line oral antihyperglycemic drug from the 
biguanide group recommended for individuals 
with type 2 DM [11–13]. This drug mechanism 
of action is to inhibit glucose production by the 
liver, reduce the absorption of glucose in the 
small intestine, and optimize the use of glucose 
in cells that will reduce blood sugar levels in the 
body [12,13]. Several recent studies have 
suggested that MET has the potential as an 
adjunct therapy to increase the effectiveness of 
TB treatment [11]. Other studies suggest that 
the use of MET combined with a TB therapy 
regimen can improve treatment success and 
reduce relapse rates in TB patients with DM 
[13,16]. 
Research in China and Korea found that the 
use of MET in TB patients with comorbid type 2 
DM will accelerate sputum culture conversion at 
the end of the second month [13]. MET is known 
to have an immunomodulatory role in reducing 
inflammation by activating AMP kinase, which 
will reduce the growth of Mtb and the area of 
damaged tissue [13,14]. Another study 
mentioned MET's role in preventing the 
formation of a persistent Mtb phenotype that 
would make this bacterium resistant to 
antituberculosis drugs by inhibiting proteins 
that function in the biosynthesis of the NDH-1 
respiration chain complex [11,13]. 
One observational literature found that 
patients who were given a combination of MET 
therapy and conventional antituberculosis had a 
7% lower risk of death even though subjects had 
an older age compared to the group without 
MET [14]. A cohort analysis showed that DM 
patients given MET had a lower risk of suffering 
from latent TB seen from the number of IFN-
gamma CFP-10 specific to fewer Mtb [11,14]. 
An observational study found that MET can 
reduce relapse rates and increase therapeutic 
success because it has the potential to kill 
intracellular Mtb that lives latently in 
macrophages by increasing phagocytosis, 
phagolysosome fusion, and autophagi from 
macrophages [13]. Also, an in vitro study 
concluded that MET-exposed macrophages 
have a higher ability to increase the production 
of reactive oxidative species (ROS) and 
mitochondrial reactive nitrogen (RNS) species 
that have mycobacteriosis contained 
intracellular and extracellular Mtb [11,13,14]. 
The P450 enzyme system does not metabolize 
MET, and the interaction between this drug and 
rifampicin will increase the expression of 
organic cation transporters (OCT1) and 
increase the uptake of liver metformin, which 
causes more controlled blood sugar levels. MET 
was also found to increase the bactericidal 
efficacy of isoniazid due to the activation of 
superoxide dismutase (SOD) and can inhibit 
stimulators for the proliferation of cancer cells 
such as insulin-like growth factor (IGF) 
accompanied by P13K-AKT activation. There is 
a positive association between MET and 
increased pyrazinamide efficacy through 
autophagy and phagocytosis of intracellular Mtb 
[16]. Therefore, the use of a combination of 
antituberculosis drugs and MET as host-
directed therapy (HDT) for TB patients with DM 
can increase the success of short-term and long-
term TB treatment [13,14,16,17]. 
3.6. Mechanism of Metformin in 
Tuberculosis Therapy  
There are several mechanisms of action of 
MET that can be used as adjunctive therapy or 
HDT in the pharmacotherapy of TB patients 
with DM, including inhibiting the growth of Mtb 
with mitochondrial ROS production, increasing 
the efficacy of conventional anti-TB drugs, 
reducing tissue damaged by TB, improving 
immune response, reduce the inflammation 
process, reduce the severity of TB, improve 
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treatment outcomes, and reduce the incidence 
of latent TB [11–17]. 
In a study [17-19] that used 13 autophagic 
drugs and AMPK activation to see the ability to 
control the growth of intracellular M. Bovis 
bacillus Calmette-Guerin (BCG) in THP-1 human 
monocyte cells using colony-forming unit (CFU) 
levels was found MET can slow the growth of 
intracellular BCG and H37Rv Mtb strains. After 
24 hours of evaluation of Mtb growth 
retardation, the MET effect stops when 
adenosine monophosphate-activated protein 
kinase (AMPK) is genetically or chemically 
activated and undergoes phosphorylation, 
regulates cell growth and antimicrobial function 
of cellular immunity. MET treatment also 
selectively activates the production of 
mitochondrial ROS triggered by inhibition of the 
mitochondrial complex I (NADH 
dehydrogenase), and this condition is proven to 
inhibit the growth of Mtb in vitro because it can 
excite the potential membrane of the 
mitochondria, release cytochrome-c into the 
cytoplasm, and initiate the intrinsic apoptotic 
pathway that ends in cell death. 
In vivo research [11,14,17] in mice with TB 
concluded that MET could increase isoniazid 
efficacy as seen from the decrease in the amount 
of Mtb in mice given MET and when compared 
to mice that were only given isoniazid. In mice 
given MET and ethambutol, CFU was found in 
the lungs and lymph, which were lower than 
mice given only ethambutol. Both of these 
results indicate that the use of MET can improve 
the effectiveness of conventional 
antituberculosis drugs. 
In the same study [14,16], pulmonary and 
lymphatic rats found with a combination of MET 
and conventional antituberculosis drugs were 
smaller than those only given conventional anti-
tuberculosis drugs, the morphological analysis 
showed that the pathology lesions were smaller 
in size. Histopathological evaluation of 
tuberculosis-infected lungs from mice not given 
MET found more diffuse lung lesions with lots of 
infiltration of macrophages, lymphocytes, and 
intracellular acid-resistant stem cells. No 
granulomas were found in mice infected with TB 
using a combination of MET and conventional 
TB drugs. 
Furthermore, an evaluation of Th1 cell 
immune response was also performed, which 
showed a higher number of CD4 and CD8 T cells 
in subjects given MET [14]. MET administration 
was also associated with an increase in the 
number and percentage of IFN-gamma 
producing CD8 cells. 
Genetic transcription analysis was also 
performed with RNA isolates in mice's lungs 
with Mtb, and there were 1580 genes expressed 
due to exposure to infection. There was a 97% 
difference in genetic expression in the two 
groups, which indicated that MET 
administration triggered a decrease in the 
response of proinflammatory mediators such as 
IL-1beta, TNF-alpha, IL-6, MCP-1, CXCL5, and 
CXCL10 [14,16,17]. 
 
4. Conclusion  
Tuberculosis is an infectious disease by a 
single microorganism with the highest 
prevalence in the world. Along with medical 
science development, lifestyle changes, and an 
aging population shifting infectious diseases 
into non-communicable diseases as a significant 
global health problem, one of them is diabetes 
mellitus. The relationship between tuberculosis 
and diabetes mellitus that influence each other 
has been known for a long time. Mortality and 
morbidity risk in individuals with TB will be 
higher if there is DM as a comorbidity.  Central 
hypothesis of TB and DM comorbidities' 
relationship is the disruption of the immune 
response and its inflammatory response. 
Metformin is an oral antidiabetic drug of 
the first line of biguanide, most commonly used 
in patients with DM. Recent studies suggest that 
metformin's potential role as host-directed 
therapy (HDT) for TB patients with DM can 
increase treatment success. The literature found 
that metformin is an immunomodulator that 
can improve the body's immune response and 
inflammatory response directly and indirectly. 
Many studies are still needed to prove the 
effectiveness of metformin as HDT for TB 
patients with DM. 
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